AI assistant
Senzime — Share Issue/Capital Change 2023
Oct 24, 2023
3198_rns_2023-10-24_b35acf7a-2a74-487c-9ce4-675c5a772081.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
PRESS RELEASE 24 October 2023 20:30:00 CEST
Senzime announces full subscription of 117 MSEK directed share issue
Senzime AB (publ) ("Senzime" or the "Company") announced on 25 September 2023 the board of directors' resolution to carry out a directed share issue of 18,000,000 shares at subscription price SEK 6.50 per share (the "Share Issue"). The subscribers in the Share Issue consisted of a number of well-established new investors (Segulah Medical Acceleration and Carnegie Fonder), as well as a few existing shareholders with a long term interest for the Company (Fjärde APfonden, Crafoordska stiftelsen, Handelsbanken Fonder, Fredrik Rapp and Swedbank Robur). The Share Issue was subject to approval from a general meeting, and such approval – which was unanimous – was obtained on the extraordinary general meeting held on 19 October 2023. Subscription and allotment of all the issued shares have now been finalized.
Through the Share Issue, the number of shares in the Company is increased from 100,122,614 to 118,122,614 shares. The share capital of the Company is increased by SEK 2,250,000, from SEK 12,515,326.75 to SEK 14,765,326.75. The Swedish Financial Supervisory Authority is currently processing a prospectus regarding admittance to trading. The new shares will be admitted to trading on Nasdaq Stockholm as soon as approval has been obtained from the Authority, which is estimated to 9 November 2023.
Advisers
In connection with the Share Issue, the Company has retained Zonda Partners as financial advisor and Advokatfirman Lindahl KB as legal adviser to the Company.
For further information, please contact:
Philip Siberg, CEO of Senzime AB Phone: +46 (0) 707 90 67 34, e-mail: [email protected]
Slavoljub Grujicic, CFO Phone: +46 (0) 76 306 60 11, e-mail: [email protected]
About Senzime
Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDAcleared patient monitoring systems. Senzime's employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.
Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at senzime.com.
Attachments
Senzime announces full subscription of 117 MSEK directed share issue